Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl
SRP-9001-303
Phase 3 small_molecule active
Quick answer
Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl for Duchenne Muscular Dystrophy is a Phase 3 program (small_molecule) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sarepta Therapeutics
- Indication
- Duchenne Muscular Dystrophy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active